Clinical Trials

Sponsor: ADC Therapeutics SA

Sponsor Study ID: ADCT-402-105

Study Title: A Phase 1b Open Label Study to Evaluate the Safety and Anti cancer Activity of Loncastuximab Tesirine in Combination with Other Anti cancer Agents in Patients with Relapsed or Refractory B cell Non Hodgkin Lymphoma (LOTIS 7)

NCT Number: NCT04970901

Phase: I

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Non-Hodgkin's Lymphoma

Study Objectives: The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with gemcitabine, lenalidomide, polazutumab vedotin, or umbralisib, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.

For more information about the trial above please contact the study team:

Principal Investigator, Brian Hess, at hessbr@musc.edu.
Study Coordinator, Sarah Britton, at brittosa@musc.edu, or please call +1 843-792-8057.

Trial opened at the following institutions: Medical University of South Carolina

Study Documents
(MUSC NetID required for document access)